All In Biotech

Drug Trial Radar · NCT05922124

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)

Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

734

Planned (sponsor's estimate)

Start

Sep 1, 2024

Primary completion

Jul 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Rambam Health Care CampusAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Monaldi Hospital; Rutgers Robert Wood Johnson Medical School; Pisa University Hospital; Assaf-Harofeh Medical Center; Sheba Medical Center
First posted
Jun 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated with colistin alone or colistin combined with meropenem.

Conditions

  • Carbapenem Resistant Bacterial Infection
  • Acinetobacter Bacteremia
  • Acinetobacter Pneumonia

Interventions

  • CefiderocolDrug

    Test drug regimen

  • Ampicillin-sulbactamDrug

    Synergistic combination

  • ColistinDrug

    Historical comparator

  • MeropenemDrug

    Historical comparator synergistic combination

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All cause mortalityTime frame: 28 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Rambam Health Care Campus

    Haifa, Israel · Recruiting

  • Sheba Tel HaShomer Medical Campus

    Ramat Gan, Israel · Recruiting

  • Shamir Medical Center (Assaf Harofeh)

    Tel Aviv, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.